IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

REDA, GIANLUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.858
NA - Nord America 3.581
AS - Asia 1.730
SA - Sud America 186
AF - Africa 27
OC - Oceania 23
Continente sconosciuto - Info sul continente non disponibili 3
Totale 11.408
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.485
DE - Germania 2.831
GB - Regno Unito 1.021
IT - Italia 753
CN - Cina 715
SG - Singapore 418
SE - Svezia 319
IN - India 183
RU - Federazione Russa 176
IE - Irlanda 162
BR - Brasile 134
FR - Francia 128
UA - Ucraina 101
CA - Canada 79
ID - Indonesia 63
FI - Finlandia 61
KR - Corea 61
TR - Turchia 56
JP - Giappone 54
HK - Hong Kong 51
PL - Polonia 47
NL - Olanda 43
CH - Svizzera 42
EU - Europa 41
DK - Danimarca 34
ES - Italia 34
VN - Vietnam 33
CO - Colombia 26
BE - Belgio 23
GR - Grecia 18
CZ - Repubblica Ceca 15
AT - Austria 14
AU - Australia 13
MX - Messico 13
IR - Iran 11
IL - Israele 10
NZ - Nuova Zelanda 10
ZA - Sudafrica 10
TH - Thailandia 9
BD - Bangladesh 8
AR - Argentina 7
MA - Marocco 7
PH - Filippine 7
PK - Pakistan 7
RO - Romania 7
TW - Taiwan 7
BG - Bulgaria 5
HR - Croazia 5
HU - Ungheria 5
CL - Cile 4
EG - Egitto 4
IQ - Iraq 4
KW - Kuwait 4
LU - Lussemburgo 4
MY - Malesia 4
UY - Uruguay 4
AM - Armenia 3
DO - Repubblica Dominicana 3
EC - Ecuador 3
OM - Oman 3
PE - Perù 3
QA - Qatar 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BO - Bolivia 2
ET - Etiopia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
LV - Lettonia 2
PT - Portogallo 2
SA - Arabia Saudita 2
UZ - Uzbekistan 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
CI - Costa d'Avorio 1
HN - Honduras 1
IS - Islanda 1
KE - Kenya 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LT - Lituania 1
NO - Norvegia 1
NP - Nepal 1
PY - Paraguay 1
RS - Serbia 1
SC - Seychelles 1
TN - Tunisia 1
Totale 11.448
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 2.321
Southend 897
Boise 588
Chandler 375
Singapore 309
Hanover 226
Milan 216
Fairfield 163
Dublin 162
Ashburn 160
Princeton 134
Wilmington 128
Beijing 123
Ann Arbor 98
Seattle 98
Woodbridge 95
Houston 88
Council Bluffs 85
Jacksonville 72
Cambridge 66
Dearborn 66
Redwood City 63
Bengaluru 53
Nanjing 53
Santa Clara 53
Des Moines 52
Toronto 51
Payette 45
Rome 44
Shanghai 44
Jakarta 39
Berlin 37
Garden Valley 37
Helsinki 35
Warsaw 32
Hong Kong 30
Phoenix 30
Redmond 30
Jerome 29
Jinan 29
New York 29
Shenyang 29
Genoa 28
Los Angeles 27
Andover 25
Mountain View 25
Orofino 24
Brussels 23
Nanchang 22
Boardman 21
Cottonwood 21
Guangzhou 21
Bogotá 19
Lewiston 19
Tokyo 19
Kent 18
Mumbai 18
Sakarya 18
Turin 18
Deiva Marina 17
Hyderabad 17
Fuzhou 16
Seoul 16
Serra 16
São Paulo 16
Kiez 15
San Diego 15
Tianjin 15
Changsha 14
Athens 13
Grafing 13
Hebei 13
Central District 12
Genova 12
Hefei 12
Madrid 12
Nordman 12
Polcenigo 12
Somerville 12
Dong Ket 11
Roxbury 11
San Jose 11
Ankara 10
Brno 10
Duncan 10
Fremont 10
San Francisco 10
Bitonto 9
Chengdu 9
Hangzhou 9
Vienna 9
Washington 9
Wuhan 9
Zhengzhou 9
Bari 8
London 8
Mannheim 8
Pavia 8
Silver Spring 8
Bühl 7
Totale 8.153
Salva come PNG Salva come JPEG
Nome #
Low dose dasatinib in refractory imatinib mesylate chronic myeloid leukemia : case report 945
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine. Results of study on 486 cases outside clinical trials 367
Assessment of the 4-factor score : Retrospective analysis of 586 CLL patients receiving ibrutinib : A campus CLL study 361
Concomitant Occurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukaemia after Lenalidomide Treatment for del(5q) Myelodysplastic Syndrome 349
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia : a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 306
Immunoglobulin heavy chain variable region gene (IGHV) and prediction of time to first treatment (TTFT) in patients with chronic lymphocytic leukemia (CLL): Mutational load or mutational status? Analysis of 1003 cases 299
FZD6 triggers Wnt-signalling driven by WNT10BIVS1 expression and highlights new targets in T cell acute lymphoblastic leukemia 279
TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases 269
Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL) : results of a prospective, single-arm multicentre study 264
Ineffective hematopoiesis and markers of angiogeneisis in myelodysplastic syndromes 232
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment 232
Ensuring continuity of care of hematologic patients during COVID-19 pandemic in a tertiary hospital in Lombardy (Italy) 223
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 219
Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia : a GIMEMA multicenter phase II trial 213
Acute idiopathic polyneuropathy after subcutaneous alemtuzumab (AL) therapy in chronic lymphocytic leukemia (CLL) patients 208
High levels of vascular endothelial growth factor protein expression are associated with an increased risk of transfusion dependence in myelodysplastic syndromes 203
Guillain Barrè syndrome in a chronic lymphocytic leukaemia (CLL) patient after subcutaneous alemtuzumab (A) therapy 200
IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia 199
Evalutation of TIE2-expressing monocytes in myeloid disorders 197
Lenalidomide in the treatment of chronic lymphocytic leukemia 192
Conjunctival hemorrhagic events associated with imatinib 191
Hepcidin levels and their determinants in different types of myelodysplastic syndromes 190
Iron metabolism and erythropoietic stress in myelodysplastic sindrome 184
Biological and molecular characterization of a rare case of cutaneous Richter syndrome 184
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2) 178
Frequency and clinical relevance of coding and noncoding NOTCH1 mutations in early stage Binet A chronic lymphocytic leukemia patients 172
Low dose campath 1-H is highly effective and safe in advanced chronic CLL 170
Multifactorial neutropenia in a patient with acute promyelocytic leukemia and associated large granular lymphocyte expansion: A case report 170
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 170
Relationship between expression of TLRS and disease activity in B-CLL 164
Myelodysplastic syndromes : microvascular density and immunohistochemical expression of the proteins controllin angiogenesis 161
Role of dasatinib in PH '-positive acute lymphoblastic leukemia (ALL) after imatinib-based therapy failure : a case report 157
Conjunctival hemorrhagic events associated with imatinib mesylate 155
Low-dose subcutaneous campath (CAM) is highly effective and safe in advanced and chemotherapy-refractory B-CLL : results of a prospectic and multicenter phase II study 151
Low-dose ALEMTUZUMAB monotherapy in advanced chronic lymphocytic leukemia 151
Low-dose Alemtuzumab in Refractory/Relapsed Chronic Lymphocytic Leukemia : Genetic Profile and Long-term Outcome from a Single Center Experience 149
Decitabine treatment for an unusual case of atypical chronic myeloid leukemia (aCML) with a concomitant chronic lymphocytic leukemia (CLL) 149
Predictors of atrial fibrillation in ibrutinib-treated CLL patients : a prospective study 145
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion : results from the National Registry of the Italian Drug Agency 144
Reduced expression of toll-like receptor 4 in B-chronic lymphocytic leukemia patients with autoimmune complications 142
Efficacy of front-line ibrutinib and rituximab combination and the impact of treatment discontinuation in unfit patients with chronic lymphocytic leukemia : results of the Gimema LLC1114 Study 141
Fludarabine-Ifosfamide-Rituximab (FIR): a therapeutic option for chronic lymphocytic leukemia patients resistant to Chlorambucil 139
Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation 134
Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations 132
Targeting WNT10B-Driven Signalling through Induction of FZD6 By Porcupine Inhibition in T Cell Acute Lymphoblastic Leukemia 132
Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia 129
Comprehensive Biological and Molecular Characterization of a RARE Case of Cutaneous Richter Syndrome 128
Idelalisib rapidly improves platelet function tests in patients with chronic lymphocytic leukaemia 124
New SMAC-Mimetic Compounds Strongly Induce In Vitro Apoptosis of Human Lymphocytes From Patients with Chronic Lymphocytic Leukemia 121
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 121
Off-Label Use of Thrombopoietin Receptor Agonists: Case Series and Review of the Literature 119
Idelalisib Rapidly Improves Platelets Function in Patients with Chronic Lymphocytic Leukemia (CLL) 118
Impact of Bone Marrow Fibrosis and Early Response on Outcome after Azacitidine Therapy in 94 Patients with Myelodisplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia 117
Impact of bone marrow fibrosis in response to azacitidine in 94 patients with myelodisplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia 116
Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia 113
Chronic lymphocytic leukemia and prognostic models : a bridge between clinical and biological markers 101
Expression of TLRs in B-CLL: Relationship with Disease Activity 100
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab 91
Secondary malignancies in chronic lymphocytic leukemia: a single centre retrospective analysis 91
Heminsight to assess patient reported outcomes of patients affected by chronic lymphocytic leukemia in daily clinical practice 88
Hypogammaglobulinemia in Chronic Lymphocytic Leukemia: A Predictor of Outcome? 85
Secondary Malignancies in Chronic Lymphocytic Leukemia: A Single Centre Retrospective Analysis of 514 Cases 84
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 74
Hypogammaglobulinemia is a strong predictor of time to first treatment in chronic lymphocytic leukemia 72
Atrial Fibrillation (AF) and Ibrutinib, a Monocentric Experience: Should Cardiological Evaluation be a Guide in Clinical Practice? 72
Lymphocytic infiltrate and p53 protein expression as predictive markers of response and outcome in myelodysplastic syndromes treated with azacitidine 61
null 6
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) 1
Totale 11.844
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.453
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.453
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020236 0 0 0 0 0 0 0 0 0 144 64 28
2020/20211.292 87 77 149 48 99 130 66 91 156 102 190 97
2021/20221.373 113 92 266 62 92 59 72 92 133 93 87 212
2022/20231.490 186 145 140 154 132 250 43 92 185 33 87 43
2023/20242.431 38 78 75 55 169 120 359 332 177 318 357 353
2024/20252.027 342 413 248 364 163 76 107 189 125 0 0 0
Totale 11.844